SCHEMBL15067280

SCHEMBL15067280

O=C(O)c1ccc(NC(=O)c2ccccc2)c(C(=O)O)c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.72
KMT2A Q03164 5/20 0.72
MAPT P10636 4/20 0.72
PKM P14618 2/20 0.72
TDP1 Q9NUW8 2/20 0.72
GRIK1 P39086 1/20 0.72
LTC4S Q16873 1/20 0.69
SERPINE1 P05121 4/20 0.68
HCAR3 P49019 1/20 0.61
DHODH Q02127 1/20 0.61
ALDH1A1 P00352 1/20 0.60
HTT P42858 1/20 0.60
GFER P55789 1/20 0.60
MCL1 Q07820 1/20 0.58
BCL2A1 Q16548 1/20 0.58
NPC1 O15118 1/20 0.57
AKR1C4 P17516 2/20 0.56
AKR1C3 P42330 2/20 0.56
AKR1C2 P52895 2/20 0.56
AKR1C1 Q04828 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12700346 0.88 HSD17B10 (0.61) MEN1KMT2AMAPTPKMTDP1
SCHEMBL21953116 0.88 SERPINE1 (0.76) MEN1KMT2AMAPTPKMTDP1
SCHEMBL30267981 0.88 SERPINE1 (0.76) MEN1KMT2AMAPTPKMTDP1
SCHEMBL6096421 0.86 MEN1 (0.74) MEN1KMT2AMAPTPKMTDP1
SCHEMBL1954779 0.86 MEN1 (0.72) MEN1KMT2AMAPTPKMTDP1
SCHEMBL14075414 0.85 MEN1 (0.70) MEN1KMT2AMAPTPKMTDP1
SCHEMBL6109346 0.84 SERPINE1 (0.77) MEN1KMT2AMAPTTDP1SERPINE1
SCHEMBL1056451 0.84 KMT2A (1.00) MEN1KMT2AMAPTPKMTDP1
SCHEMBL11834604 0.83 MEN1 (0.85) MEN1KMT2AMAPTPKMTDP1
SCHEMBL6351321 0.83 SERPINE1 (0.89) MEN1KMT2AMAPTPKMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2797930-B1 FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-07-13 EP disclosed
US-9206177-B2 Substituted dimeric quinazoline-2,4-diones as FGF receptor agonists SANOFI (FR) 2015-12-08 US disclosed
US-9206177-B2 Substituted dimeric quinazoline-2,4-diones as FGF receptor agonists SANOFI (FR) 2015-12-08 US disclosed
US-20140378483-A1 FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof SANOFI (FR) 2014-12-25 US disclosed
US-20140378483-A1 FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof SANOFI (FR) 2014-12-25 US disclosed
EP-2797930-A1 FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-11-05 EP disclosed
WO-2013098763-A1 FGF RECEPTOR (FGFR) AGONIST DIMERIC COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378483-A1 FGF Receptor (FGFR) Agonist Dimeric Compounds, Process for the Preparation Thereof and Therapeutic Use Thereof FGFR1, FGFR2, FGF2 MEN1 1168/4885KMT2A 2004/4885MAPT 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.